Oncologists’ Costs For Three Drugs Would Exceed Reimbursement – GAO
Executive Summary
Acquisition costs for three chemotherapy drugs would exceed projected Medicare reimbursement rates in 2005, a Government Accountability Office analysis using preliminary average sales price data finds
You may also be interested in...
CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B
Medicare Part B Demo, Coding Changes Will Stabilize Oncology Rx Market
The Centers for Medicare & Medicaid Services expects the combination of a new oncology "quality of care" demonstration project and the adoption of new billing codes to help smooth the transition to ASP-based reimbursement in 2005
Average Sales Price Unveiled; IG Will Monitor Part B Market In 2005
The HHS Inspector General will monitor prices for drugs covered under Medicare Part B to determine whether the "average sales price" accurately reflects market prices once payment rates for 2005 are finalized this fall